ArticleFood science & nutrition2025
2'-Fucosyllactose Modulates the Intestinal Immune Response to Gut Microbiota and Buffers Experimental Colitis in Mice: An Integrating Investigation of Colonic Proteomics and Gut Microbiota Analysis.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Microbiota-Derived Regulation of AhR and VDR Signaling in Intestinal Inflammation: Protective Roles of Prebiotics, Probiotics, and Postbiotics.International journal of molecular sciences · 2026Review
- Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut.Frontiers in immunology · 2026Review
- Deciphering the Potential Mechanism of Cordycepin in Alleviating Ulcerative Colitis via the AKT1 Signaling Pathway: An Integrated Approach Combining Network Pharmacology, Molecular Docking, and Experimental Validation.Journal of inflammation research · 2026Article
- Gastrointestinal Journey of Human Milk Oligosaccharides: From Breastfeeding Origins to Functional Roles in Adults.Microorganisms · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), a recurrent gastrointestinal disease, is characterized by dysbiosis and inflammation. 2'-fucosyllactose (2'-FL) shows benefits in maintaining gut microenvironment homeostasis. This study aims to investigate the protective mechanism of 2'-FL against experimental IBD using integrated analysis of colonic proteomics and microbiota 16S rRNA sequencing technologies. A murine model of experimental colitis was induced by dextran sodium sulfate (DSS) for 7 days (day 0-day 7). 2'-FL (250 mg/kg/d) was orally administered for 7 days. On day 7, all mice were sacrificed and their colon tissues were collected for morphological examination and label-free quantitative proteomics analysis. The fecal samples were collected for microbiota 16S rRNA sequencing. 2'-FL significantly ameliorated DSS-induced pathological damage and restored the epithelial integrity of colon tissues in mice. Colonic proteomics and GO analysis showed 681 differentially expressed proteins (DEPs) in response to 2'-FL administration. These DEPs were mainly enriched to GO terms of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.